Designation of Midostaurin (Rydapt) as an Orphan Drug

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods in Australia, ensuring they are of acceptable quality, safety, and efficacy. This Act, administered by the Therapeutic Goods Administration under the Department of Health, aims to provide a comprehensive framework for the control and regulation of therapeutic goods, including medicines, medical devices, and other health-related products. One of the critical aspects of this Act is its provision for the designation of orphan drugs, which are medications developed to treat rare medical conditions. The designation of midostaurin (RYDAPT) as an orphan drug on 22 June 2016 under the Therapeutic Goods Act 1989, specifically through the Therapeutic Goods Regulations 1990, addresses the gap in treatment options for rare conditions such as newly diagnosed acute myeloid leukaemia (AML) with FLT3 mutation in patients eligible for standard chemotherapy, and aggressive systemic mastocytosis or mast cell leukaemia, with or without associated haematologic non-mast cell lineage disorders. The policy objective behind this designation is to incentivise the development of treatments for rare diseases by providing certain benefits and support to the sponsor, in this case, Novartis Pharmaceuticals Australia Pty Limited.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Commonwealth of Australia, provides a comprehensive framework for the regulation of therapeutic goods in Australia. This Act applies to all therapeutic goods, which encompass a wide range of products including medicines, medical devices, blood and blood components, tissues, and vaccines. Its jurisdiction extends nationally, ensuring that all therapeutic goods available in Australia meet the required safety, quality, and efficacy standards. The Act applies to entities and individuals involved in the manufacturing, importation, supply, and advertising of these goods. Notably, the designation of midostaurin (RYDAPT) as an orphan drug under this Act is specifically for its use in treating newly diagnosed acute myeloid leukaemia (AML) in FLT3 mutation-positive patients and aggressive systemic mastocytosis (ASM) or mast cell leukaemia (MCL). This designation facilitates the development and availability of treatments for rare conditions by offering certain incentives and expedited review processes. The application of the Act can be further refined and extended through subordinate instruments such as regulations and guidelines, which provide additional detail on the specific requirements and processes for different types of therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989, through its Regulations, provides a framework for the regulation of therapeutic goods in Australia. In this context, Section 16J of the Therapeutic Goods Regulations 1990 allows for the designation of certain therapeutic goods as orphan drugs, which are intended for the treatment of rare diseases. In this specific case, Dr. Anthony Gill, as a Delegate of the Secretary, has designated midostaurin (RYDAPT) as an orphan drug on 22 June 2016. This designation is for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are Fms-like Tyrosine Kinase 3 (FLT3) mutation-positive, as well as for aggressive systemic mastocytosis (ASM) or mast cell leukaemia (MCL), with or without an associated hematologic non-mast cell lineage disorder (AHNMD). The drug will be administered in capsule form, and the sponsor of midostaurin (RYDAPT) is Novartis Pharmaceuticals Australia Pty Limited. The designation of midostaurin (RYDAPT) as an orphan drug brings with it certain obligations and requirements for the parties involved. The Therapeutic Goods Regulations 1990 impose certain obligations on the sponsor of the drug, in this case, Novartis Pharmaceuticals Australia Pty Limited. These obligations include ensuring that the therapeutic goods are safe and of high quality, and that they meet the requirements of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. The sponsor must also ensure that the therapeutic goods are accompanied by appropriate labelling and documentation, and that they are manufactured in accordance with Good Manufacturing Practice (GMP) standards. Failure to comply with the requirements of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in civil or criminal penalties. The Act provides for a range of penalties, including fines and imprisonment, for breaches of its provisions. For example, section 34 of the Act provides that a person who contravenes a direction given under the Act or the Regulations is guilty of an offence and is liable to a fine of up to $22,200 for an individual or $111,000 for a body corporate. Section 35 of the Act provides that a person who is found guilty of an offence against the Act is liable to imprisonment for up to two years, or both imprisonment and a fine. In addition, the Act provides for the imposition of civil penalties, such as pecuniary penalties and injunctions, for breaches of its provisions. In conclusion, the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 provide a framework for the regulation of therapeutic goods in Australia, including the designation of orphan drugs such as midostaurin (RYDAPT) for the treatment of rare diseases. The designation of midostaurin (RYDAPT) as an orphan drug brings with it certain obligations and requirements for the parties involved, and failure to comply with these obligations can result in civil or criminal penalties. It is important for those involved in the manufacture, supply, and distribution of therapeutic goods to be aware of their obligations under the Act and the Regulations, and to ensure that they comply with these obligations in order to avoid the risk of penalties.